Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.

Schievink B, de Zeeuw D, Parving HH, Rossing P, Lambers Heerspink HJ.

Br J Clin Pharmacol. 2015 Oct;80(4):678-86. doi: 10.1111/bcp.12655. Epub 2015 May 28.

2.

Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.

McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D.

Am J Kidney Dis. 2014 Nov;64(5):714-22. doi: 10.1053/j.ajkd.2014.06.008. Epub 2014 Jul 24.

PMID:
25064674
3.

Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.

Riphagen IJ, Deetman PE, Bakker SJ, Navis G, Cooper ME, Lewis JB, de Zeeuw D, Lambers Heerspink HJ.

Diabetes. 2014 Aug;63(8):2845-53. doi: 10.2337/db13-1652. Epub 2014 Mar 27.

4.

Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.

Hartner A, Cordasic N, Klanke B, Menendez-Castro C, Veelken R, Schmieder RE, Hilgers KF.

Biochim Biophys Acta. 2014 Apr;1842(4):558-65. doi: 10.1016/j.bbadis.2014.01.001. Epub 2014 Jan 10.

5.

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.

Gialama F, Maniadakis N.

Vasc Health Risk Manag. 2013;9:575-92. doi: 10.2147/VHRM.S50831. Epub 2013 Oct 7. Review.

6.

[Irbesartan in clinical practice].

Malishevskiĭ MV.

Kardiologiia. 2012;52(11):66-74. Review. Russian.

PMID:
23237398
7.

Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.

Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, Gutierrez E; PRONEDI Study Group.

Am J Kidney Dis. 2013 Feb;61(2):211-8. doi: 10.1053/j.ajkd.2012.07.011. Epub 2012 Aug 29.

PMID:
22939518
8.

Aggressive blood pressure-lowering therapy guided by home blood pressure monitoring improves target organ damage in hypertensive patients with type 2 diabetes/prediabetes.

Eguchi K, Hoshide S, Ishikawa S, Shimada K, Kario K.

J Clin Hypertens (Greenwich). 2012 Jul;14(7):422-8. doi: 10.1111/j.1751-7176.2012.00648.x. Epub 2012 May 18.

9.

Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.

Evans M, Bain SC, Hogan S, Bilous RW; Collaborative Study Group participants.

Nephrol Dial Transplant. 2012 Jun;27(6):2255-63. doi: 10.1093/ndt/gfr696. Epub 2011 Dec 15.

PMID:
22172728
10.

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.

Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ.

Eur Heart J. 2011 Jun;32(12):1493-9. doi: 10.1093/eurheartj/ehr017. Epub 2011 Mar 18.

PMID:
21421598
11.

Renal protection with angiotensin receptor blockers: where do we stand.

Schmieder RE, Ruilope LM, Barnett AH.

J Nephrol. 2011 Sep-Oct;24(5):569-80. doi: 10.5301/JN.2011.6445. Review.

PMID:
21404225
12.

The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression.

Chen HB, Lu JX, Li Q, Bao YQ, Tang JL, Lu HJ, Xiang KS, Jia WP.

Acta Pharmacol Sin. 2009 Feb;30(2):242-50. doi: 10.1038/aps.2008.28. Epub 2009 Jan 26.

13.

Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.

Cetinkalp SS, Karadeniz MM, Erdogan MA, Ozgen GA, Yilmaz CO.

Saudi Med J. 2008 Oct;29(10):1414-8.

PMID:
18946564
14.

Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Croom KF, Plosker GL.

Drugs. 2008;68(11):1543-69. Review.

PMID:
18627212
15.

[Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].

Busch M, Franke S, Stein G, Wolf G; Collaborative Study Group.

Dtsch Med Wochenschr. 2007 Sep;132(36):1810-4. German.

PMID:
17726651
16.
17.
18.

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

Curr Med Res Opin. 2006 Nov;22(11):2095-100.

PMID:
17076969
19.

[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].

Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H.

Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1721-6. German.

PMID:
16868875
20.

Supplemental Content

Loading ...
Support Center